Reducing the Rates of Prescribing High-dose Antipsychotics and Polypharmacy on Psychiatric Inpatient and Intensive Care Units: Results of a 6-year Quality Improvement Programme

Overview

Journal Ther Adv Psychopharmacol

Specialty Psychiatry

Date 2015 Feb 6

PMID 25653825

Citations 11

Authors

Shubhra Mace

David Taylor

Affiliations

Soon will be listed here.

Abstract

Background: There is no conclusive evidence that either high doses or combinations of antipsychotics are more effective than standard doses or monotherapy alone. Nonetheless, prescription of both remains prevalent in the UK. In 2006 the South London and Maudsley NHS Foundation Trust (SLAM) participated in a national survey of prescription of antipsychotic medications, organized by the Prescribing Observatory for Mental Health. Over half of the patients on SLAM inpatient or psychiatric intensive care units were prescribed a high-dose antipsychotic or a combination of antipsychotics. Prescribing high-dose antipsychotics and polypharmacy in SLAM was found to be among the highest in the UK.

Aim: To assess the impact of a 6-year quality improvement programme aimed at reducing the rates of prescribing high-dose antipsychotics and polypharmacy on SLAM inpatients and psychiatric intensive care units.

Results: There was a significant reduction between baseline and final survey in the rates of prescription of both high-dose antipsychotics and polypharmacy on SLAM inpatients and intensive care units (58% versus 10% p < 0.0001 and 57% versus 16%, p < 0.0001 respectively). The proportion of patients at final survey prescribed a high-dose antipsychotic and a combination was substantially lower in SLAM than in the national sample (10% versus 28%, p < 0.0001 and 16% versus 38%, p < 0.0001 respectively).

Clinical Implications: A sustained change in the prescribing culture of an organization can be achieved through a targeted improvement programme.

Citing Articles

Prescription patterns in psychiatric compulsory care: polypharmacy and high-dose antipsychotics.

Kaikoushi K, Karanikola M, Middleton N, Bella E, Chatzittofis A BJPsych Open. 2021; 7(5):e149.

PMID: 34747353 PMC: 8388008. DOI: 10.1192/bjo.2021.982.

Drug-naïve first-episode schizophrenia spectrum disorders: Pharmacological treatment practices in inpatient units in Hunan Province, China.

Zhu M, Ferrara M, Tan W, Shang X, Syed S, Zhang L Early Interv Psychiatry. 2020; 15(4):1010-1018.

PMID: 32924286 PMC: 8359180. DOI: 10.1111/eip.13046.

Risk Factors of Metabolic Syndrome Among Patients Receiving Antipsychotics: A Retrospective Study.

Hammoudeh S, Al Lawati H, Ghuloum S, Iram H, Yehya A, Becetti I Community Ment Health J. 2019; 56(4):760-770.

PMID: 31884574 PMC: 7089884. DOI: 10.1007/s10597-019-00537-y.

Antipsychotics and risk of natural death in patients with schizophrenia.

Chen Y, Yang X, Qin X, Yang Q, Fan H, Li J Neuropsychiatr Dis Treat. 2019; 15:1863-1871.

PMID: 31308678 PMC: 6617553. DOI: 10.2147/NDT.S199748.

Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare.

Kadra G, Spiros A, Shetty H, Iqbal E, Hayes R, Stewart R J Psychopharmacol. 2018; 32(11):1191-1196.

PMID: 30232932 PMC: 6238161. DOI: 10.1177/0269881118796809.

References

Barnes T, Paton C . Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011; 25(5):383-99. DOI: 10.2165/11587810-000000000-00000. View

Correll C, Frederickson A, Kane J, Manu P . Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res. 2006; 89(1-3):91-100. PMC: 2718048. DOI: 10.1016/j.schres.2006.08.017. View

Sparshatt A, Jones S, Taylor D . Quetiapine: dose-response relationship in schizophrenia. CNS Drugs. 2007; 22(1):49-68. DOI: 10.2165/00023210-200822010-00004. View

Correll C, Rummel-Kluge C, Corves C, Kane J, Leucht S . Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2008; 35(2):443-57. PMC: 2659301. DOI: 10.1093/schbul/sbn018. View

Elliott R, Woodward M, Oborne C . Improving benzodiazepine prescribing for elderly hospital inpatients using audit and multidisciplinary feedback. Intern Med J. 2002; 31(9):529-35. DOI: 10.1046/j.1445-5994.2001.00139.x. View

Grol R, Grimshaw J . From best evidence to best practice: effective implementation of change in patients' care. Lancet. 2003; 362(9391):1225-30. DOI: 10.1016/S0140-6736(03)14546-1. View

Ito H, Koyama A, Higuchi T . Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry. 2005; 187:243-7. DOI: 10.1192/bjp.187.3.243. View

Kane J, HONIGFELD G, Singer J, Meltzer H . Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45(9):789-96. DOI: 10.1001/archpsyc.1988.01800330013001. View

Charani E, Edwards R, Sevdalis N, Alexandrou B, Sibley E, Mullett D . Behavior change strategies to influence antimicrobial prescribing in acute care: a systematic review. Clin Infect Dis. 2011; 53(7):651-62. DOI: 10.1093/cid/cir445. View

10.

Conley R, Carpenter Jr W, Tamminga C . Time to clozapine response in a standardized trial. Am J Psychiatry. 1997; 154(9):1243-7. DOI: 10.1176/ajp.154.9.1243. View

11.

Mace S, Taylor D . Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS Drugs. 2009; 23(9):773-80. DOI: 10.2165/11310820-000000000-00000. View

12.

Baldessarini R, Cohen B, Teicher M . Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1988; 45(1):79-91. DOI: 10.1001/archpsyc.1988.01800250095013. View

13.

Chakrabarti A, Whicher E, Morrison M, Douglas-Hall P . 'As required' medication regimens for seriously mentally ill people in hospital. Cochrane Database Syst Rev. 2007; (3):CD003441. DOI: 10.1002/14651858.CD003441.pub2. View

14.

Essock S, Hargreaves W, Covell N, Goethe J . Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull. 1996; 32(4):683-97. View

15.

Waddington J, Youssef H, Kinsella A . Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry. 1999; 173:325-9. DOI: 10.1192/bjp.173.4.325. View

16.

Essock S, Schooler N, Stroup T, McEvoy J, Rojas I, Jackson C . Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011; 168(7):702-8. PMC: 3739691. DOI: 10.1176/appi.ajp.2011.10060908. View

17.

Kinon B, Volavka J, Stauffer V, Edwards S, Liu-Seifert H, Chen L . Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008; 28(4):392-400. DOI: 10.1097/JCP.0b013e31817e63a5. View

18.

Thompson A, Sullivan S, Barley M, Strange S, Moore L, Rogers P . The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards - a cluster randomized controlled trial. Psychol Med. 2007; 38(5):705-15. DOI: 10.1017/S003329170700147X. View

19.

Carnahan R, Lund B, Perry P, Chrischilles E . Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand. 2006; 113(2):135-41. DOI: 10.1111/j.1600-0447.2005.00589.x. View

20.

Ezewuzie N, Taylor D . Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol. 2005; 20(1):86-90. DOI: 10.1177/0269881105057001. View